erlotinib hydrochloride has been researched along with l 733060 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (l 733060) | Trials (l 733060) | Recent Studies (post-2010) (l 733060) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 71 | 0 | 32 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | l 733060 (IC50) |
|---|---|---|---|
| Substance-P receptor | Homo sapiens (human) | 0.001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, D; Hu, JL; Liu, XP; Ren, H; Wang, JG; Yang, WL; Yu, J; Zhang, L | 1 |
1 other study(ies) available for erlotinib hydrochloride and l 733060
| Article | Year |
|---|---|
Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptors, Neurokinin-1; RNA Interference; RNA, Small Interfering; Signal Transduction; Substance P; Triple Negative Breast Neoplasms | 2015 |